Panavir® 0.002g of 3% gel for local and external application
The instruction for medical use of PANAVIR® medicine the Trade name of Panavir® the International unlicensed name Is not present the Dosage form Gel for external and topical administration 0.002% 3 g or 30 g Structure 100 g of gel contain active agent: Панавир® (polysaccharides of escapes Solanum tuberosum)-0.002 g, excipients: glitserol, macrogoal 4000, macrogoal 400, ethanol of 95%, sodium hydroxide, lanthanum nitrate hexahydrate, water. The description Homogeneous mass of white color with a slight specific smell. The pharmacotherapeutic group Antiviral means of plant origin the ATX D06BB Code the Pharmacological Pharmacokinetics Pharmacokinetics properties of this dosage form of drug was not studied. A pharmacodynamics of Panavir® – the purified extract of sprouts of a plant Solanum tuberosum, the main active ingredient – the hexose glycoside consisting of glucose, rhamnose, pectine sugar, mannose, xylose, a galactose, uronic acids. The drug Panavir® has virusostatichesky effect. It is active concerning the Herpes simplex viruses of types I and II. Suppresses replication and polimerazny reactions of viruses, blocking synthesis of virus DNA in the struck cells of skin and/or mucous membranes. Tests showed lack of mutagen, teratogenic, cancerogenic, allergenic and embriotoksichesky action. In preclinical trials on laboratory animals of negative impact on reproductive function and fetation it is not established. Indications – the infectious and inflammatory diseases of skin and/or mucous membranes caused by a virus of a herpes simplex Herpes simplex of types I and II (including genital herpes) – a human papillomavirus infection of skin and/or mucous membranes of genitalias and perianal area in a combination with laser destruction of peaked condylomas the Route of administration and doses – outwardly and locally – gel apply with a thin layer on affected areas of skin and/or mucous membranes – for treatment infectious – the inflammatory diseases of skin and/or mucous membranes caused by a virus of a herpes simplex Herpes simplex of types I and II (including genital herpes) – 5 times a day within 4-5 days. The course of treatment can be prolonged up to 10 days. – for treatment of a human papillomavirus infection – 2 times a day within 5 days to and 10 days after laser destruction of condylomas Side effects – emergence of quickly taking place reddening and an itching of skin and/or mucous membranes on the site of putting gel is possible If you noticed any other side effects which are not specified in the instruction, report about it to the doctor. Contraindications – individual intolerance and hypersensitivity to drug components – children’s age up to 18 years Medicinal interactions are not registered. Treatment at perhaps early stage of a disease Is recommended to begin special instructions, at the first signs (itching, pricking, reddening, feeling of tension), in this case development of a bubble stage of a disease can be completely prevented. The drug Panavir® cannot be used in ophthalmology. When putting gel on the person to avoid its hit in eyes. Pregnancy and the period of breastfeeding Use during pregnancy is possible only when the expected advantage for mother exceeds potential risk for a fruit. In need of use of drug in the period of a lactation the breastfeeding for the period of administration of drug should be stopped. The feature of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms does not influence. Overdose Cases of overdose are not revealed. A release form Gel for external and topical administration of 0.002%. On 3 g or 30 g of drug in a tuba aluminum with internal varnish coating together with the instruction for medical use in the state and Russian languages place in a pack from cardboard bandbox. To Store storage conditions in the dry, protected from light place, at a temperature from 2 to 25 °C. To store out of children’s reach! Period of storage 3 years. Not to use after the expiry date specified on packing. Prescription status Without prescription Russia CJSC Zelenaya dubrava Producer, 141800, Moscow Region, Dmitrov, Professionalnaya St., 151. Owner of the registration certificate of LLC National Research Company Russia, 301404, Tula Region, Suvorov area, of Varushitsa, 104. The address of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers on quality of products (goods) and responsible for post-registration observation of safety of medicine of Shamsun LLP, Republic of Kazakhstan, 050052, Almaty, Teplichnaya St., 12/16, apartment 1, ph. 8 (727) 239-19-59, e-mail: Amanzholov.Shamsun@gmail.com.